-
Detailed Description
CAS Number: 104376-79-6
Molecular Formula: C18H16N8O7S3 · 2Na · 3.5 H2O
Molecular Weight: 661.60 g/mol
Mechanism of Action: Like β-lactams, cephalosporins interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to cephalosporins is commonly due to cells containing plasmid encoded β-lactamases. Like many cephalosporins, ceftriaxone is resistant to a number of β-lactamases. Ceftriaxone can be used to study PBPs.
Storage Conditions: -20°C
Tariff Code: 2941.90.5000
-
Applications
Spectrum: Ceftriaxone Sodium is a broad-spectrum antibiotic targeting a wide variety of Gram-positive and Gram-negative bacteria. In comparison to the first and second generation cephalosporins, this third-generation compound is more active against Gram-negative bacteria than Gram-positive bactria.
Microbiology Applications: Ceftriaxone Sodium is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include:
- Streptococcus pneumoniae 0.03 µg/mL - 8 µg/mL
- Streptococcus pyogenes 0.008 µg/mL – 0.5 µg/mL
- For a representative list of Ceftriaxone MIC values, click here.
Eukaryotic Cell Culture Applications: During in vitro studies with hippocampal astrocytes, researchers found that Ceftriaxone promoted the nuclear translocation of p65 as well as the activation of Akt. It modulated EAAT2 expression (Excitatory Amino Acid Transporter 2) via PI3K/Akt/NF-κB signaling pathway. It may exert protective effects against early brain injury following subarachnoid hemorrhage (SAH).(Feng et al, 2014).
Using in vitro models with primary human fetal astrocytes, researchers found Ceftriaxone has a neuroprotective effect and can ameliorate specific neurodegenerative diseases by increasing the update of glutamate, an essential neurotransmitter regulating brain function. It stimulates the expression of one of the major glutamate transporters (Excitatory Amino Acid Transporter or EAAT2) via a signaling pathway called the nuclear factor-kB pathway (Lee et al, 2008). -
Specifications
Form: Powder
Appearance: Off-white to yellow crystalline powder
Source: Synthetic
Water Content (Karl Fischer): 8.0-11.0%
pH: 6.0-8.0
Assay: (On Dried Basis): ≥795 µg/mg
Identification: Conforms
-
Technical Data
Solubility: Freely soluble in aqueous solution (105 mg/mL), sparingly soluble in methanol, and very slightly soluble in ethanol.
Residual Solvents: N,N-Dimethylanilline: Not more than 20ppm
2-Ethylhexanoic acid: Not more than 0.8%Impurity Profile: N,N-Dimethylanilline: ≤20ppm
2-Ethylhexanoic acid: ≤0.8% -
References
References:
Feng D et al (2014) Ceftriaxone alleviates early brain injury after subarachnoid hemorrhage by increasing excitatory amino acid transporter 2 expression via the P13K/Akt/NF-kB signaling pathway. Neurosci. 268:21-32
Georgopapadakou, NH (1992) Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli. Antimicrob. Agents Chemother. 37(3): 559-565
Lee S et al (2008) Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J. Biol. Chem 283: 13116-13123Richards DM, Heel RC, Brogden RN, Speight TM and Avery GS (1984) Ceftriaxone: A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 27(6):469-527 PMID: 6329638
Ruzza P et al (2016) Interactions of GFAP with ceftriaxone and phenytoin: SRCD and molecular docking and dynamic simulation. Biochim. Biophys. Acta. 1860(10):2239-2248 PMID 27133445
Ceftriaxone Sodium, USP is the sodium salt form of Ceftriaxone, a semisynthetic, broad-spectrum, third-generation cephalosporin antibiotic that can be used in proteomics, the study of penicillin-binding proteins, and biosynthetic pathway investigation. This β-lactam is a cefotaxime derivative. The product is formulated as Ceftriaxone Sodium hemi(heptahydrate) and is freely soluble in aqueous solution.
We also offer:
- Ceftriaxone Free Acid (C074)
Ceftriaxone Sodium, USP conforms to United States Pharmacopeia specifications.
CAS Number: 104376-79-6
Molecular Formula: C18H16N8O7S3 · 2Na · 3.5 H2O
Molecular Weight: 661.60 g/mol
Mechanism of Action: Like β-lactams, cephalosporins interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to cephalosporins is commonly due to cells containing plasmid encoded β-lactamases. Like many cephalosporins, ceftriaxone is resistant to a number of β-lactamases. Ceftriaxone can be used to study PBPs.
Storage Conditions: -20°C
Tariff Code: 2941.90.5000
Spectrum: Ceftriaxone Sodium is a broad-spectrum antibiotic targeting a wide variety of Gram-positive and Gram-negative bacteria. In comparison to the first and second generation cephalosporins, this third-generation compound is more active against Gram-negative bacteria than Gram-positive bactria.
Microbiology Applications: Ceftriaxone Sodium is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include:
- Streptococcus pneumoniae 0.03 µg/mL - 8 µg/mL
- Streptococcus pyogenes 0.008 µg/mL – 0.5 µg/mL
- For a representative list of Ceftriaxone MIC values, click here.
Eukaryotic Cell Culture Applications: During in vitro studies with hippocampal astrocytes, researchers found that Ceftriaxone promoted the nuclear translocation of p65 as well as the activation of Akt. It modulated EAAT2 expression (Excitatory Amino Acid Transporter 2) via PI3K/Akt/NF-κB signaling pathway. It may exert protective effects against early brain injury following subarachnoid hemorrhage (SAH).(Feng et al, 2014).
Using in vitro models with primary human fetal astrocytes, researchers found Ceftriaxone has a neuroprotective effect and can ameliorate specific neurodegenerative diseases by increasing the update of glutamate, an essential neurotransmitter regulating brain function. It stimulates the expression of one of the major glutamate transporters (Excitatory Amino Acid Transporter or EAAT2) via a signaling pathway called the nuclear factor-kB pathway (Lee et al, 2008).
Form: Powder
Appearance: Off-white to yellow crystalline powder
Source: Synthetic
Water Content (Karl Fischer): 8.0-11.0%
pH: 6.0-8.0
Assay: (On Dried Basis): ≥795 µg/mg
Identification: Conforms
Solubility: Freely soluble in aqueous solution (105 mg/mL), sparingly soluble in methanol, and very slightly soluble in ethanol.
Residual Solvents: N,N-Dimethylanilline: Not more than 20ppm
2-Ethylhexanoic acid: Not more than 0.8%
Impurity Profile: N,N-Dimethylanilline: ≤20ppm
2-Ethylhexanoic acid: ≤0.8%
References:
Feng D et al (2014) Ceftriaxone alleviates early brain injury after subarachnoid hemorrhage by increasing excitatory amino acid transporter 2 expression via the P13K/Akt/NF-kB signaling pathway. Neurosci. 268:21-32
Georgopapadakou, NH (1992) Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli. Antimicrob. Agents Chemother. 37(3): 559-565
Lee S et al (2008) Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J. Biol. Chem 283: 13116-13123
Richards DM, Heel RC, Brogden RN, Speight TM and Avery GS (1984) Ceftriaxone: A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 27(6):469-527 PMID: 6329638
Ruzza P et al (2016) Interactions of GFAP with ceftriaxone and phenytoin: SRCD and molecular docking and dynamic simulation. Biochim. Biophys. Acta. 1860(10):2239-2248 PMID 27133445